The Most Common Side Effect of Testosterone Therapy Is One You Can't Feel

Erythrocytosis is the most common side effect of testosterone therapy.[1] It means an excess of red blood cells, it is measured as hematocrit on a standard blood panel, and it is asymptomatic in its early stages. A clinical consultation guide in European Urology Focus puts the action threshold plainly: providers should decrease or discontinue therapy if hematocrit exceeds 54%, until it normalises.[1]

That single number is the most actionable thing on this page.

Why testosterone raises red cell count

Testosterone stimulates erythropoiesis — the production of red blood cells. This is a normal pharmacological effect, not a sign of anything going wrong, and it is dose-related. Read from the other end, the same mechanism is a treatment: in men who are hypogonadal and anemic, testosterone corrects the anemia significantly more often than placebo. One effect, two clinical meanings, decided by where the patient started.

The timing is well characterised. Effects on erythropoiesis become evident at three months and peak at nine to twelve months.[2] That is precisely why the monitoring schedule is shaped the way it is: the three-month panel is the first point at which the effect is measurable, and the later draws catch it near its maximum. See the 3-month panel.

The 54% threshold

The consultation guide's recommendation is to decrease or discontinue testosterone therapy when hematocrit exceeds 54%, and to hold until it normalises.[1] It also notes that patient-specific factors should inform the choice of dose and modality in the first place.[1]

The Endocrine Society guideline approaches the same risk from the other end: elevated hematocrit is listed among the conditions under which testosterone therapy should not be started at all.[3] A man whose hematocrit is already high before treatment is not a candidate until that is addressed.

What raises the risk

Several factors stack with treatment, and most are worth knowing before you start:

Untreated obstructive sleep apnea. Low overnight oxygen drives red cell production independently. The guideline lists untreated severe obstructive sleep apnea among the conditions under which therapy should not be started.[3]

Smoking. Another independent driver of erythrocytosis, through the same low-oxygen mechanism.

Dose and formulation. The consultation guide's framing is that patient-specific factors should shape both the dosage and the modality chosen.[1]

A baseline already at the top of the range. There is less headroom before the threshold.

What happens if yours is high

This is a conversation with your prescriber, not a reason to stop unilaterally. The published guidance is to reduce or discontinue and re-check until hematocrit normalises.[1] Depending on the cause, the response may involve a dose change, a change of formulation, addressing an untreated contributor like sleep apnea, or — in some cases — therapeutic phlebotomy under clinical direction.

What it is not is something to manage yourself. The threshold exists because the risk it represents is a vascular one — higher hematocrit means higher blood viscosity, which is the proposed mechanism behind the association between testosterone therapy and venous clots.

Frequently asked questions

Is high hematocrit the same as polycythemia? In practice the terms get used interchangeably for this side effect, though "erythrocytosis" is the more precise word for a raised red cell mass secondary to something else — here, testosterone. True polycythemia vera is a distinct bone-marrow disorder.

Will I feel it if my hematocrit is climbing? Generally not, early on. That is the reason it is monitored on a schedule rather than reported by symptoms.

Does it go away if I stop? The published guidance is to hold therapy until hematocrit normalises, which implies it is expected to come down off treatment.[1] Timing and follow-up are for your clinician.

Does donating blood fix it? Reducing red cell mass is one of the clinical levers, but doing it on your own initiative rather than under direction means the underlying cause is not being assessed — and the dose that produced it is unchanged.

Where this fits in monitoring

Hematocrit sits alongside serum testosterone, symptom and adverse-effect review, compliance, and prostate cancer risk assessment in the guideline's standardised first-year monitoring plan.[3] It is one item on a short list, and the one with a published number attached.

Keen connects you with a licensed clinical team for a telehealth consultation and lab review. If your testosterone is clinically low, treatment is Keen Testosterone Spray Rx — a once-daily topical spray powered by Hypospray® transdermal delivery.

Related reading: the 3-month panel and TRT and fertility.

References

3 sources

1. Agrawal P, Singh SM, Kohn T. Management of Erythrocytosis in Men Receiving Testosterone Therapy: Clinical Consultation Guide. Eur Urol Focus. 2023;9(1):20–21. doi:10.1016/j.euf.2022.10.008 · PMID 36335038
2. Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165(5):675–685. doi:10.1530/EJE-11-0221 · PMID 21753068
3. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229 · PMID 29562364